Lululemon Athletica Inc (NASDAQ:LULU) continues to see strong customer interest in new products, but weaker foot traffic has weighed on its outlook, analysts say.
The athleticwear company’s shares are down more than 14% on Friday following yesterday’s earnings release that showcased weak first-quarter guidance, overshadowing its stronger-than-expected fourth-quarter results.
Nike Inc (NYSE:NKE, ETR:NKE) is poised for a major comeback, according to Jefferies analysts who recently issued a "Buy" rating for the company with a price target of $115.
This represents a potential upside of approximately 75% from its current share price of $65.80.
Walt Disney Co (NYSE:DIS, ETR:WDP) has earned a repeat ‘Buy’ rating from analysts at Bank of America, who remain optimistic about the entertainment giant’s growth prospects in 2025.
The analysts awarded the stock a $140 price target. Shares traded hands at about $98 on Friday.
Century Lithium Corp. (TSX-V:LCE, OTCQX:CYDVF), the owner of the Angel Island lithium project in Nevada, is poised to benefit from the inevitable upturn in lithium demand and pricing, analysts at Noble Capital Markets believe.
“Angel Island is one of a few advanced lithium projects being developed in the United States to provide an end-to-end process to produce battery-grade lithium,” analysts wrote.
JP Morgan expects Novo Nordisk (NYSE:NVO) to hold the line on its 2025 growth targets when it reports first-quarter results, saying a reaffirmation of guidance would help calm nerves after a sluggish start to the year for weight-loss drug Wegovy in the US.
Analyst Richard Vosser forecasts sales of DKr77.1bn, around 4% below Bloomberg consensus estimates, largely due to lower expectations for both Wegovy and diabetes treatment Ozempic.